**European Society for Medical Oncology Congress**

**Monday, September 20**

- **Mini Oral session - Melanoma and other skin tumors**
  - **Xu B**
    - Cancer (ABC) human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer: PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs letrozole (LET) alone.

**Saturday, September 18**

- **Mini Oral session - Breast cancer, metastatic**
  - **Saad F**
    - Patient (pt) reported pain in men with metastatic castration resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm)—exploration of non-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in patients (Pts) with DDRm mutated.
  - **Armstrong AJ**
    - Overall survival (OS) from ARCHES: Final analysis of the phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019.
- **Palbociclib**
  - **Rugo HS**
    - Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across PALOMA-2 (Pal) + letrozole (LET) vs letrozole (LET) alone.
  - **Dawood SH**
    - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older women with hormone receptor–positive, HER2–negative advanced breast cancer (ABC).
- **Talazoparib**
  - **Mehra N**
    - DDRm mutational landscape and potential associations with antitumor activity in patients with metastatic breast cancer (mBC).
  - **Agarwal N**
    - Talazoparib (TALA) vs placebo (PBO) plus ENZA in patients (Pts) with DDR gene mutated.

**Tuesday, September 21**

- **Proffered Paper session - Sars-CoV-2 and cancer**
  - **Hurvitz SA**
    - Real-world comparative effectiveness of relugolix: a subgroup analysis from the randomized, phase 3 HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC).

**Wednesday, September 22**

- **Talazoparib**
  - **Rogers AW**
    - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic breast cancer (MBC): a real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology therapy for patients with advanced urothelial cancer (aUC).
  - **Bilen MA**
    - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic breast cancer (MBC): a real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology therapy for patients with advanced urothelial cancer (aUC).
  - **Rocque GB**
    - Treatment patterns in Black and Indigenous people and people of color (BIPOC) receiving treatment for hormone receptor–positive, HER2–negative advanced breast cancer (ABC) in a real-world setting: POLARIS review.
  - **Ayeni Y**
    - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older women with hormone receptor–positive, HER2–negative advanced breast cancer (ABC).
- **Enzalutamide**
  - **Patient (pt) reported pain in men with metastatic castration resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm)—exploration of non-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in patients (Pts) with DDRm mutated.
- **Lorlatinib**
  - **Horwich LD**
    - First-line treatments and clinical outcomes for hormone receptor-positive, human epidermal growth factor 2-positive advanced or metastatic breast cancer: a systematic literature review.
- **Relugolix**
  - **Wang MH**
    - Geographical assessment of efficacy and safety of relugolix: a subgroup analysis from the randomized, phase 3 HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC).

**Friday, September 23**

- **Pfizer Oral Presentations**
  - **Dummer R**
    - Binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with mutant melanoma.
  - **Husseini I**
    - TALAPRO-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in patients (Pts) with DDR gene mutated.
  - **Husseini I**
    - TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm).
  - **Husseini I**
    - TALAPRO-2: Talazoparib (TALA) for patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutation.

**COVID-19/Pan-Oncology**

**Tuesday, September 21**

- **Proffered Paper session - Sars-CoV-2 and cancer**
  - **Bilen MA**
    - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic breast cancer (MBC): a real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology therapy for patients with advanced urothelial cancer (aUC).

**Note:** All materials are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.